Interferon-free treatments in patients with hepatitis C genotype 3 infection in a tertiary hospital
| Autor: | del Rio-Valencia, Juan Carlos, Asensi-Diez, Rocío, Madera-Pajin, Raquel, Yunquera-Romero, Lucía, Muñoz-Castillo, Isabel |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Interferon-free treatments
Adult Liver Cirrhosis Male Genotype Original Hepacivirus VHC Antiviral Agents Cohort Studies Tertiary Care Centers Ribavirin Humans genotype 3 tratamiento libre interferon Aged Retrospective Studies Fluorenes genotipo 3 Middle Aged Hepatitis C Drug Combinations HCV Benzimidazoles Female Interferons Sofosbuvir Uridine Monophosphate |
| Zdroj: | Revista Española de Quimioterapia |
| ISSN: | 1988-9518 0214-3429 |
| Popis: | Introduction Hepatitis C virus genotype 3 represents a unique entity within HCV treatment and multiple studies have documented that HCV genotype 3 infection is associated with more rapid disease progression than other genotypes, resulting in increased risk of cirrhosis, hepatocellular carcinoma, and all-cause mortality. In the current study, we further evaluated the real-world effectiveness of 12 weeks of ledipasvir/sofosbuvir ± ribavirin (LDV/SOF ± RBV) and sofosbuvir + daclatasvir (SOF + DCV) for treatment-naive or treatment-experienced patients infected with HCV genotype 3, with or without cirrhosis. Material and methods Retrospective and observational study carried out in a third level hospital. Study period: April 2015 to January 2016. Inclusion criteria: Patients with HCV genotype-3 infection treated either with LDV/SOF ± RBV or with SOF + DCV during study period treated for 12 weeks. The patients that were treated during 24 weeks were excluded and those treated with peg-interferon. The main endpoint measured was the sustained virologic response (SVR) at 12 weeks (SVR12) and the secondary endpoint was SVR at 24 weeks (SVR24). Results During the study period, 603 patients were treated in our hospital: 71 with genotype 3. We included 46 patients who were treated with LDV/SOF ± RBV or SOF + DCV for 12 weeks. A 43.75% (7/16) of all patients treated with LDV/SOF achieved SVR12, 90% (9/10) of the patients treated with LDV/SOF+RBV achieved SVR12 and 95% (19/20) of the patients treated with SOF+DCV achieved SVR12. There was statistically significant difference (p=0.001) between LDV/SOF respect to SOF+DCV and between LDV/SOF with regard to LDV/SOF +RBV (p=0.018) used to treat HCV genotype 3 infection. Conclusions In conclusion, in our cohort of patients, the combination of SOF + DCV followed by LDV/SOF + RBV 12 weeks were the most effective in patients with HCV genotype 3 and with cirrhosis (SVR12 90% and 80%, respectively) and in those without cirrhosis (SVR12 100% in both combinations). All patients who achieved SVR12 also achieved SVR24, regardless of the regimen received. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|